Comparative assessment of medical resource use and costs associated with patients with symptomatic peripheral artery disease in the United States

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 6, 2016, Pages 667-675

  Chase, Monica Reed ^a   Friedman, Howard S ^b   Navaratnam, Prakash ^b   Heithoff, Kim ^a   Simpson, Ross J ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Data Solutions LLC   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CLOPIDOGREL;

AGED; ARTICLE; BRAIN ISCHEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIAGNOSIS RELATED GROUP; DRUG USE; ENDOVASCULAR SURGERY; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH CARE UTILIZATION; HOSPITAL PATIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ICD-9-CM; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESOURCE ALLOCATION; RETROSPECTIVE STUDY; REVASCULARIZATION; UNITED STATES; UNSTABLE ANGINA PECTORIS; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE PLANNING; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PROCEDURES; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; FEMALE; HEALTH RESOURCES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84977508270     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.15010     Document Type: Article

References (14)

1. Shammas NW. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease. Vasc Health Risk Manag. 2007;3(2):229-34.
2. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197-208.
3. Diehm C, Allenberg JR, Pittrow D, et al. Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation. 2009;120(21):2053-61.
4. Allison MA, Ho E, Denenberg JO, et al. Ethnic-specific prevalence of peripheral arterial disease in the United States. Am J Prev Med. 2007;32(4):328-33.
5. Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010:a systematic review and analysis. Lancet. 2013;382(9901):1329-40.
6. Toscani MR, Makkar R, Bottorff MB. Quality improvement in the continuum of care: impact of atherothrombosis in managed care pharmacy. J Manag Care Pharm. 2004;10(6 Suppl A):S2-12; quiz S13-16. Available at:http://www.amcp.org/data/jmcp/Novsupp1.pdf.
7. Margolis J, Barron JJ, Grochulski WD. Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data. J Manag Care Pharm. 2005;11(9):727-34. Available at: http://amcp.org/data/jmcp/research_727-734.pdf.
8. Mahoney EM, Wang K, Keo HH, et al. Vascular hospitalization rates and costs in patients with peripheral artery disease in the United States. Circ Cardiovasc Qual Outcomes. 2010;3(6):642-51.
9. Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008;1(1):38-45.
10. Malyar N, Furstenberg T, Wellmann J, et al. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J. 2013;34(34):2706-14.
11. Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2011;58(19):2020-45.
12. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2(degrees)P-TIMI 50. Circulation. 2013;127(14):1522-29, 29e1-6.
13. Cambou JP, Aboyans V, Constans J, et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France:the COPART Registry. Eur J Vasc Endovasc Surg. 2010;39(5):577-85.
14. Azarbal A, Clavijo L, Gaglia MA Jr. Antiplatelet therapy for peripheral arterial disease and critical limb ischemia: guidelines abound, but where are the data? J Cardiovasc Pharmacol Ther. 2015;20(2):144-56.